Viking Therapeutics, Inc.
NASDAQVKTX cost to borrow surges 136% in one week to 0.65%, still cheap despite spike as stock rallies 36%.
Snapshot as of 23 Sept 2026
Viking Therapeutics enters September with nearly 20% of its free float sold short and options traders leaning more bullish than they have been in months — a split that makes the stock's positioning more nuanced than…
Viking Therapeutics heads into the back half of July with a stock down 11% on the week, a short base stubbornly above 20% of the float, and options traders who look distinctly unconcerned about further downside. The…
Viking Therapeutics has rallied 17% in a week while nearly 20% of its float remains short — a setup where an unmoved short base meets visibly bullish options positioning. The stock closed at $34.81 on Tuesday, up 7.5%…
Viking Therapeutics enters the post-earnings stretch with its heaviest short position in months still intact — even as the stock slipped further following a wider-than-expected Q1 loss. Short sellers have not blinked.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VKTX — free to start on ORTEX.
Sign up for free →Open VKTX on ORTEX